Recent Updates
Recently added Catalysts
SPRB Positive Sentiment

Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spruce Biosciences has announced the separation of its CRHX-101 program into a new subsidiary named Adrenyx Biosciences. This move aims to create a dedicated focus on endocrinology. Adrenyx will operate as a wholly-owned subsidiary of Spruce, enhancing the company's strategic direction in addressing unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Spruce Biosciences formed a new subsidiary, Adrenyx.
  • Adrenyx will focus on endocrinology.
  • The separation aims to enhance operational focus.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
6.4%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
SPR001
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has separated the company's CRHX-101 (formerly SPR-202) program into Adrenyx Biosciences, Inc. ("Adrenyx"), a newly formed wholly-owned subsidiary of Spruce that will operate as a dedicated endocrinology company (the "Separation

Frequently Asked Questions

What is Adrenyx Biosciences?

Adrenyx Biosciences is a new subsidiary formed from Spruce's CRHX-101 program.

Why did Spruce separate CRHX-101?

The separation aims to create a dedicated focus on endocrinology.

What will Adrenyx focus on?

Adrenyx will operate as an endocrinology company.

Is Adrenyx a subsidiary of Spruce?

Yes, Adrenyx is a wholly-owned subsidiary of Spruce Biosciences.

ShareAdd on Google
Tags: SPRB Spruce Biosciences CRHX-101 endocrinology biopharmaceuticals
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$96M liquidity · $7M/mo burn
~10 mo
Medium dilution risk
Lead asset
SPR001Phase 2
Congenital Adrenal Hyperplasia →

Catalyst track record

+41%
best trade around SPRB's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SPRB.

See every catalyst's timing & PoA →